LT2012006A - 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui - Google Patents
500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymuiInfo
- Publication number
- LT2012006A LT2012006A LT2012006A LT2012006A LT2012006A LT 2012006 A LT2012006 A LT 2012006A LT 2012006 A LT2012006 A LT 2012006A LT 2012006 A LT2012006 A LT 2012006A LT 2012006 A LT2012006 A LT 2012006A
- Authority
- LT
- Lithuania
- Prior art keywords
- fulvestrant
- dosage
- treatment
- breast cancer
- advanced breast
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title abstract 2
- 238000009261 endocrine therapy Methods 0.000 abstract 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Šis išradimas susijęs su 500 mg dozės fulvestrantu, skirtu panaudoti gydyme moterų po menopauzės su išplitusiu krūties vėžiu, kuris progresavo arba recidyvavo endokrininės terapijos metu.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2012006A true LT2012006A (lt) | 2013-03-25 |
| LT5953B LT5953B (lt) | 2013-07-25 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2012006A LT5953B (lt) | 2009-07-27 | 2012-01-24 | 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20120214778A1 (lt) |
| EP (1) | EP2459199A1 (lt) |
| JP (1) | JP2013500324A (lt) |
| KR (1) | KR20120042843A (lt) |
| AT (1) | AT510868A2 (lt) |
| AU (1) | AU2010277373A1 (lt) |
| BG (1) | BG111123A (lt) |
| BR (1) | BR112012001837A2 (lt) |
| CA (1) | CA2768286A1 (lt) |
| CL (1) | CL2012000226A1 (lt) |
| CZ (1) | CZ201235A3 (lt) |
| DE (1) | DE112010003084T5 (lt) |
| DK (1) | DK201270089A (lt) |
| EA (1) | EA201200190A1 (lt) |
| EC (1) | ECSP12011629A (lt) |
| EE (1) | EE201200003A (lt) |
| ES (1) | ES2393323A1 (lt) |
| FI (1) | FI20125207A7 (lt) |
| GB (2) | GB0912999D0 (lt) |
| HR (1) | HRP20120084A2 (lt) |
| HU (1) | HUP1200203A3 (lt) |
| IL (1) | IL217527A0 (lt) |
| IS (1) | IS8994A (lt) |
| LT (1) | LT5953B (lt) |
| MX (1) | MX2012001282A (lt) |
| NO (1) | NO20120147A1 (lt) |
| PE (1) | PE20121177A1 (lt) |
| PL (1) | PL399129A1 (lt) |
| RO (1) | RO128705A2 (lt) |
| RS (1) | RS20120022A1 (lt) |
| SE (1) | SE1250155A1 (lt) |
| SG (1) | SG177586A1 (lt) |
| SK (1) | SK500052012A3 (lt) |
| TR (1) | TR201200950T1 (lt) |
| WO (1) | WO2011012885A1 (lt) |
| ZA (1) | ZA201201406B (lt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP2017515873A (ja) * | 2014-05-21 | 2017-06-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法 |
| WO2017201189A1 (en) * | 2016-05-17 | 2017-11-23 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| MX386903B (es) * | 2016-10-21 | 2025-03-19 | Crescita Therapeutics Inc | Composiciones farmacéuticas tópicas y uso en el tratamiento de afecciones cutáneas. |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en not_active Ceased
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 FI FI20125207A patent/FI20125207A7/fi not_active Application Discontinuation
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 RS RS20120022A patent/RS20120022A1/sr unknown
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Withdrawn
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| TW201711676A (en) | Ferric citrate dosage forms | |
| TW201611831A (en) | Novel antitumoral use of CABAZITAXEL | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| ZA201007648B (en) | Progesterone antagonists such as cdb-4124 in the treatment of breast cancer | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| LT2012006A (lt) | 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui | |
| MX2012012523A (es) | Lactonas esteroideas anticancerigenas insaturadas en la posicion 7(8). | |
| HUE031337T2 (hu) | Opioidok rezisztens rákos betegek kezelésében történõ alkalmazásra | |
| MX2011009804A (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. | |
| MX343222B (es) | Combinacion de teobrina con un descongestionante y su uso para el tratamiento de la tos. | |
| MX2012005849A (es) | Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d. | |
| MX2015004759A (es) | Fosfestrol para uso en el tratamiento curativo o paliativo de cancer en mamiferos hembras. | |
| IN2015KN00676A (lt) | ||
| JO3550B1 (ar) | مركب لمعالجة سرطان البروستاتا | |
| UA44831U (ru) | Способ лечения женщин, больных гипертонической болезнью в сочетании с сахарным диабетом ii типа | |
| UA66404U (ru) | Способ профилактики и лечения остеопороза у беременных с перинатальным инфицированием | |
| MY174794A (en) | Anticancer composition | |
| UA82250U (ru) | Способ лечения больных с неалкогольной жировой болезнью печени | |
| TN2010000464A1 (en) | Dronedarone for the prevention of cardioversion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Patent application published |
Effective date: 20130325 |
|
| FG9A | Patent granted |
Effective date: 20130725 |
|
| MM9A | Lapsed patents |
Effective date: 20140726 |